Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates

One thing we could say about the analysts on DBV Technologies S.A. (EPA:DBV) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.

Following the latest downgrade, the current consensus, from the three analysts covering DBV Technologies, is for revenues of US$6.4m in 2024, which would reflect a stressful 59% reduction in DBV Technologies' sales over the past 12 months. Losses are supposed to balloon 26% to US$0.95 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$8.1m and losses of US$0.85 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

Check out our latest analysis for DBV Technologies

earnings-and-revenue-growth
ENXTPA:DBV Earnings and Revenue Growth March 14th 2024

Analysts lifted their price target 7.3% to €5.34, implicitly signalling that lower earnings per share are not expected to have a longer-term impact on the stock's value.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One more thing stood out to us about these estimates, and it's the idea that DBV Technologies' decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 59% to the end of 2024. This tops off a historical decline of 18% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 35% annually. So while a broad number of companies are forecast to grow, unfortunately DBV Technologies is expected to see its sales affected worse than other companies in the industry.

Advertisement

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at DBV Technologies. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. The increasing price target is not intuitively what we would expect to see, given these downgrades, and we'd suggest shareholders revisit their investment thesis before making a decision.

That said, the analysts might have good reason to be negative on DBV Technologies, given a short cash runway. Learn more, and discover the 2 other warning signs we've identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:DBV

DBV Technologies

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

High growth potential with excellent balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2533.3% undervalued
157 users have followed this narrative
0 users have commented on this narrative
26 users have liked this narrative
HA
HarishPK
DOX logo
HarishPK on Amdocs ·

Why Amdocs is a high conviction Buy for me?

Fair Value:US$82.0328.6% undervalued
35 users have followed this narrative
3 users have commented on this narrative
12 users have liked this narrative
IV
SBMO logo
Ivoed on SBM Offshore ·

Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog

Fair Value:€44.527.2% undervalued
18 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.723.9% undervalued
47 users have followed this narrative
3 users have commented on this narrative
20 users have liked this narrative

Updated Narratives

RO
RockeTeller
SSV logo
RockeTeller on Southern Silver Exploration ·

302 Million Oz Silver Project in Mexico: Low Cost Underground Giant Ready to Explode

Fair Value:CA$32.198.0% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
J_
J_Tyrader
OSCR logo
J_Tyrader on Oscar Health ·

7/8/26 — Oscar Health: Trading 95.4% below Fair Value with +2070.2% Upside Potential

Fair Value:US$583.3495.2% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
andre_santos
PG logo
andre_santos on Procter & Gamble ·

Procter & Gamble - A Fundamental Valuation

Fair Value:US$107.5235.6% overvalued
26 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28020.0% undervalued
273 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9119.1% overvalued
141 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0942.2% undervalued
166 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative